A Phase 3b Continuation Study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients With Severe Hemophilia A
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006554/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To continue the evaluation of the safety and efficacy of BAX 855 for prophylaxis and
treatment of bleeding episodes in adult and pediatric previously treated patients (PTPs) aged
≤ 75 years of age with severe hemophilia A.
提供机构：
Vivli
创建时间：
2021-01-19
